Wolfe Raises Eli Lilly Price Target to $1325 on Drug Hope

Wolfe Research Boosts Eli Lilly Target on Obesity Drug Outlook

Wolfe Research has increased its price target for Eli Lilly to $1325 from $1250, maintaining an Outperform rating on the stock. This revision is driven by a larger perceived commercial opportunity for the company's experimental oral obesity drug, orforglipron.

Revised Revenue Projections

The analyst's confidence is based on higher long-term sales estimates for orforglipron. Wolfe now projects the drug could generate peak annual revenue of approximately $44 billion. This is a significant increase from its previous forecast of $32 billion and is substantially higher than the consensus estimate of about $26 billion.

Impact on Market Position

This optimistic forecast underscores Eli Lilly's potential to continue its dominance in the lucrative weight-loss market. The success of an oral treatment could expand patient access and solidify the company's leadership within its cardiometabolic portfolio, creating a strong competitive advantage.

Forward Outlook

The upgraded price target reflects strong confidence in Eli Lilly's growth trajectory, especially within its obesity treatment pipeline. Investors will be closely watching for further clinical data on orforglipron to validate these bullish expectations.

FAQ

Q: What is the new price target for Eli Lilly from Wolfe Research?
A: The new price target is $1325 per share, up from $1250.

Q: Why was Eli Lilly's price target increased?
A: The increase was due to higher projected peak annual sales for its oral obesity drug, orforglipron, which are now estimated at $44 billion.

Source: Investing.com